Article

High-frequency near-infrared diode laser irradiation attenuates IL-1 β -induced expression of inflammatory cytokines and matrix metalloproteinases in human primary chondrocytes

Shuzo Sakata, Ryo Kunimatsu*, Yuji Tsuka, Ayaka Nakatani, Tomoka Hiraki, Hidemi Gunji, Naoto Hirose, Makoto Yanoshita, Nurul Aisyah Rizky Putranti, Kotaro Tanimoto

Department of Orthodontics and Craniofacial Developmental Biology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan

* Correspondence: ryoukunimatu@hiroshima-ua.c.jp; Tel.: +81-82-257-5686; Fax: +81-82-257-5687

Abstract: High-frequency near-infrared diode laser provides high peak output, low heat accumulation, and efficient biostimulation. Although these characteristics are considered suitable for osteoarthritis (OA) treatment, the effect of high-frequency near-infrared diode laser in *in vitro* or *in vivo* OA models has not yet been reported. Therefore, we aimed to assess the biological effects of high-frequency near-infrared diode laser irradiation on IL-1β-induced chondrocyte inflammation in an *in vitro* OA model. Normal Human Articular Chondrocyte-Knee (NHAC-Kn) cells were stimulated with human recombinant IL-1β and irradiated with high-frequency near-infrared diode laser (910 nm, 4 or 8 J/cm²). The mRNA and protein expression of relevant inflammation- and cartilage destruction-related proteins was analyzed. IL-1β treatment significantly increased the mRNA levels of IL-1β, IL-6, TNF-α, MMP-1, MMP-3, and MMP-13. High-frequency near-infrared diode laser irradiation significantly reduced the IL-1β-induced expression of IL-1β, IL-6, TNF-α, MMP-1, and MMP-3. Similarly, high-frequency near-infrared diode laser irradiation decreased the IL-1β-induced increase in protein expression and secreted levels of MMP-1 and MMP-3. These results highlight the therapeutic potential of high-frequency near-infrared diode laser in OA.

Keywords: high-frequency near-infrared diode laser; osteoarthritis; inflammation; matrix metalloproteinase; human chondrocyte

1. Introduction

Osteoarthritis (OA) is well-known articular joint disease often resulting in joint pain and disability in adults. Worldwide, 10% of the people older than 60 years are estimated to manifest OA symptoms [1]. Furthermore, OA has been shown to be associated with aging, overweight and obesity, cartilage injuries, and genetic factors [2-4]. Mechanical stress-induced inflammation plays an important role in OA. Synovitis in the articular condylar surface followed by secretion of inflammatory cytokines such as interleukin 1β (IL- 1β) from synovial cells is considered to be the initial stage of OA [5]. The secreted IL- 1β infiltrates the cartilage and synovial fluid, causing chondrocyte inflammation [6]. The next stage of OA involves cartilage degradation, particularly extracellular matrix (ECM) destruction by matrix metalloproteinases (MMPs) secreted from inflammatory chondrocytes [7]. IL- 1β , tumor necrosis factor alpha (TNF- α), and MMPs are considered as catabolic factors for the erosion and proteolysis of cartilage ECM components, including collagen type II and aggrecan [8, 9]. Therefore, current studies focus on the coordination, upregulation, or downregulation of these anabolic and catabolic factors for of the development of new therapeutic approaches for OA [10, 11]. Decreased joint lubrication is also involved in initial OA stages. We previously investigated the mechanism involved in OA and reported that the protein

lubricant superficial zone protein (SZP) localizes on the temporomandibular joint surface [12]. We also demonstrated that excessive mechanical loading lowers SZP production [13]; increases the friction coefficient; increases MMP-1, 3, and 9 production; and destroys substrates such as type II collagens, aggrecan, and hyaluronic acid [14, 15].

Standard treatments for knee OA include oral NSAIDs, intra-articular corticosteroid or hyaluronic acid injection, and surgery [16-18]; however, the international clinical guidelines lack consensus. To identify novel OC therapeutic approach, we investigated the possibility and mechanism underlying OA inflammation reduction by drug administration. Celecoxib, a selective COX-2 inhibitor, is known to exert protective effects on ECM metabolism in mandibular condylar chondrocytes under excessive mechanical stress [19]. Decactinib, a FAK inhibitor, and semaphorin 3A were shown to inhibit inflammation in chondrocytes under cyclic tensile strain (CTS) [20][21]. However, allopathic drugs cause adverse effects such as upper gastrointestinal complications [22], myocardial infarction, and renal insufficiency [23], whereas joint injection and surgery involve tissue injury risk. Therefore, physical therapies such as ultrasound [24], electrical stimulation [25], exercise [26], spa therapy [27], and low-level laser therapy (LLLT) have been introduced. LLLT is listed as a nonpharmacological and noninvasive treatment option for OA [28], and intensive LLLT offers clinically relevant short-term pain relief for knee OA [29-31].

Recently, high-frequency near-infrared diode laser devices, including short pulse lasers (nanosecond order), have been developed [32, 33]. These devices produce low-level output, high peak power, and no thermal damage to the treated tissue and enable efficient light penetration into the tissue [32, 33]. High-frequency near-infrared diode laser irradiation enhanced proliferation and migration of human gingival epithelial cells [34] and mouse calvarial osteoblasts [35], promoted epithelialization and bone formation in tooth extraction sockets, possibly by activating cell proliferation and differentiation in vivo [36], and reduced temporomandibular joint pain [37, 38]. Moreover, high-frequency near-infrared diode laser irradiation of periodontal tissue leads to metabolic activation, thereby increasing the tooth movement rate in rats [39]. Thus, high-frequency near-infrared diode laser irradiation may affect chondrocyte metabolism. Compared to LLLT, highfrequency near-infrared diode laser enables high efficiency and access to deeper tissues owing to the high intensity of the laser [18] and generates high peak output power. Furthermore, it does not cause excessive heat accumulation in the target tissue, thus overcoming an important concern for clinicians using laser therapies. Therefore, high-frequency near-infrared diode laser therapy may be considered as a novel, effective, and safe therapy for OA. However, the effect of high-frequency near-infrared diode laser on OA cartilage has not yet been reported. Therefore, in this study, we investigated the effect of high-frequency near-infrared diode laser irradiation on the expression of inflammatory cytokines and MMPs in an in vitro OA model and attempted to highlight the potential of such laser devices in OA treatment.

2. Materials and Methods

2.1. Cell Culture

Normal Human Articular Chondrocyte-Knee (NHAC-Kn) (CC-2550; Lonza, Walkersville, MD, USA) were cultured in chondrocyte basal medium (Chondrocyte Growth Medium BulletKitTM; CC-3217; Lonza) supplemented with 10% fetal bovine serum (FBS; CC-3217; Lonza), chondrocyte growth factors (0.2% R3-IGF-1, 0.5% hrFGF-β, 0.1% transferrin, 0.2% insulin) (CC-3217; Lonza), and 0.1% gentamycin/amphotericin B (CC-3217; Lonza) in an atmosphere containing 5% CO₂. The culture medium was changed every other day until the cells reached 80% confluence. The cells were then detached from the dish surface using trypsin/EDTA solution (Chondrocyte ReagentPackTM; CC-3233; Lonza) and transferred to new dishes. The cells were subcultured according to the manufacturer's instruction, and passage 5 cells were used for all the experiments.

2.2. Laser irradiation

A high-frequency pulsed laser with 910 nm wavelength, 45 W maximum output power, 300 mW average output power, 200 ns pulse width, 30 kHz pulse repetition rate, and 9.6 cm² irradiation area (Lumix 2; USA Laser Biotech, Inc., Richmond, VA, USA) was used for the experiment. The output was monitored using a LabMax-TOP laser power meter (Coherent NA, Inc., Wilsonville, OR, USA) connected to a PM10 power sensor (Coherent NA, Inc.). The equipment also emits a light with 650 nm wavelength as the guiding wavelength.

NHAC-Kn cells were seeded (1 × 10 5 cells/well) in 6-well plates (Becton Dickinson, Franklin Lakes, NJ, USA), and cultured in chondrocyte basal medium supplemented with 10% FBS, chondrocyte growth factors (0.2% R3-IGF-1, 0.5% hrFGF- β , 0.1% transferrin, 0.2% insulin), and 0.1% gentamycin/amphotericin B. At 80% confluence , the cells were starved in serum- and growth factor-free chondrocyte basal medium for 24 h. The cells were treated with 10 pg/mL recombinant human IL-1 β (PeproTech, Rocky Hill, NJ, USA) for 4 h (for gene expression analysis) or 20 h (for protein expression analysis) and irradiated at 0, 4, or 8 J/cm², and cultured for 12 h without FBS.

2.3. Quantitative real-time polymerase chain reaction analysis

The mRNA levels of IL-1 β , IL-6, TNF- α , MMP-1, MMP-3, MMP-9, and MMP-13 were determined by quantitative real-time PCR analysis using a LightCycler system (Roche Diagnostics, Basel, Switzerland) and QuantiTect SYBR Green PCR Master Mix (Qiagen, Tokyo, Japan). Briefly, total RNA was extracted from cultured NHAC-Kn cells using an RNeasy Mini Kit and reverse transcribed using the ReverTra Ace kit (Toyobo, Osaka, Japan). Real-time PCR was performed using a Thunderbird STBR qPCR Mix (Toyobo) with specific primer sets (Table 1). The relative mRNA levels were analyzed using the $\Delta\Delta$ Ct method and normalized to beta actin (ACTB) mRNA levels.

2.4. 2-Color western blot analysis

Total protein was extracted from cultured NHAC-Kn cells using RIPA lysis buffer (Nacalai Tesque, Kyoto, Japan) supplemented with 1% (v/v) protease inhibitor cocktail. The cell lysates were centrifuged at 4 °C at 15,000 g for 20 min, and protein concentrations in the supernatant were measured using the bicinchoninic acid assay (BCA Protein Assay kit, Thermo Fisher Scientific, Rockford, IL, USA). Equal amounts of protein were electrophoresed on 10% polyacrylamide gels (e-PAGEL, ATTO, Tokyo, Japan) and transferred to PVDF membranes using iBlot 2 Gel Transfer Device and iBlot 2 Transfer stacks (Thermo Fisher Scientific) according to the manufacturer's instructions. Membranes were then blocked with 5% skim milk for 30 min at room temperature. The membranes were incubated overnight at 4 °C with primary antibodies against MMP-1 (Abcam, Cambridge, MA, USA; Cat# ab139332), MMP-3 (Abcam; Cat# ab52915), and β -actin (Wako, Osaka, Japan) and then incubated with Alexa Fluor 680-labeled anti-rabbit secondary antibody (LI-COR, Lincoln, NE, USA) or IRDye 800-labeled anti-mouse secondary antibody (LI-COR). Protein bands were detected using the Odyssey® infrared imaging system (LI-COR); band intensities were quantitated using the ImageJ software and normalized to β -actin band intensity.

2.5. Enzyme-linked immunosorbent assay (ELISA)

Here, 80% confluent NHAC-Kn cells were cultured in serum- and growth factor-free chondrocyte basal medium for 24 h and then treated with IL-1 β for 12 h. Then, the cells were irradiated at 8 J/cm², cultured for 12 h, and the culture supernatants were collected and stored at -80 °C until analysis. Levels of secreted MMP-1 and MMP-3 were measured using the MMP-1 (AB215083, Abcam) and MMP-3 (BMS2014/3, Thermo Fisher Scientific) ELISA kits respectively, following the manufacturer's recommendations, followed by measurement of the absorbance at 570 nm using a microplate reader.

2.6. Statistical analysis

Data are represented as mean \pm SEM. Groups were compared using one-way ANOVA followed by Dunnett's post hoc test; P < 0.05 was considered to indicate statistical significance.

3. Results

3.1. Effect of high-frequency near-infrared diode laser irradiation on gene expression of inflammatory cytokines in NHAC-Kn cells

qPCR analysis showed that mRNA expression levels of IL-1 β , IL-6, and TNF- α were significantly upregulated in NHAC-Kn cells treated with IL-1 β for 4 h. However, the mRNA levels of IL-1 β , IL-6, and TNF- α in the IL-1 β -stimulated chondrocytes laser irradiated at 4 and 8 J/cm² were significantly lower than those in all the other cell groups. These results indicate that laser irradiation significantly attenuated the IL-1 β -induced upregulation of these inflammatory cytokines (Fig. 1).

Fig. 1




Figure 1. Effect of high-frequency near-infrared diode laser irradiation on IL-1β-induced gene expression of inflammatory cytokines in NHAC-Kn cells. The chondrocytes were treated with IL-1β (10 pg/mL) and laser irradiated (0, 4, 8 J/cm²) for 4 h, followed by real-time PCR analysis. mRNA expression of (A) IL-1β, (B) IL-6, and (C) TNF- α are represented as mean ± SEM of three independent experiments (n = 3). *p < 0.05 compared to the IL-1β group.

3.2. Effect of high-frequency near-infrared diode laser irradiation on gene expression of MMPs in NHAC-Kn cells

To evaluate the effect of high-frequency near-infrared diode laser irradiation on the expression of genes associated with cartilage destruction, we investigated MMP-1, MMP-3, MMP-9, and MMP-13 mRNA levels in irradiated NHAC-Kn cells. The MMP-1, MMP-3, and MMP-13 mRNA levels were significantly increased by IL-1 β stimulation (Fig. 2). The MMP-1 and MMP-3 mRNA levels in IL-1 β -stimulated cells irradiated at 4 or 8 J/cm² were lower than those in the IL-1 β -stimulated cells (Fig. 2A and B); such an effect was not observed for MMP-13 (Fig. 2D). No statistically significant changes were observed in the MMP-9 mRNA levels of NHAC-Kn cells (Fig. 2C).




Figure 2. Effect of high-frequency near-infrared diode laser irradiation on IL-1β-induced gene expression of matrix metalloproteinases (MMPs) in NHAC-Kn cells. The chondrocytes were treated with IL-1β (10 pg/mL) and laser irradiated (0, 4, 8 J/cm²) for 4 h, followed by real-time PCR analysis. mRNA expression of (A) MMP-1, (B) MMP-3, (C) MMP-9, and (D) MMP-13 are represented as mean \pm SEM of three independent experiments (n = 3). *p < 0.05 compared to the IL-1β group.

3.3. Effect of high-frequency near-infrared diode laser irradiation on protein expression of matrix metalloproteinases in NHAC-Kn cells

Next, we measured the protein expression of MMP-1 and MMP-3 using western blot analysis. The protein expression of MMP-1 and MMP-3 in the IL-1 β -stimulated chondrocytes was significantly higher than that in the control cells. Similar to qPCR results, protein expression of MMP-1 and MMP-3 in IL-1 β -stimulated cells irradiated at 8 J/cm² was significantly lower than that in the IL-1 β -stimulated cells (Fig 3). In addition, we performed ELISA to evaluate the levels of MMP-1 and MMP-3 secreted in the cell culture supernatant. Secreted MMP-1 and MMP-3 levels in the IL-1 β group were considerably higher than those in the control group (Fig. 4). However, secreted MMP-1 and MMP-3 levels in the IL-1 β -stimulated cells irradiated at 8 J/cm² were significantly lower than those in the IL-1 β -stimulated cells (Fig. 4).




Figure 3. Effect of high-frequency near-infrared diode laser irradiation on IL-1β-induced protein expression of matrix metalloproteinases (MMPs) in NHAC-Kn cells. The chondrocytes were treated with IL-1β (10 pg/mL) and laser irradiated (0, 8 J/cm²) for 20 h, followed by 2-color western blot analysis. Infrared images of the antibody-treated membranes for (A) MMP-1 (red) and (B) MMP-3 (red). Band intensities of MMP-1 and MMP-3 were semi-quantified using β-actin (green) band intensity. Relative expression levels of (C) MMP-1 and (D) MMP-3 normalized to the corresponding levels in the IL-1β group and represented as mean \pm SEM of three independent experiments (n = 3). *p < 0.05 compared to the IL-1β group.




Figure 4. Effect of high-frequency near-infrared diode laser irradiation on levels of secreted matrix metalloproteinases (MMPs) in NHAC-Kn cells. The chondrocytes were treated with IL-1 β (10 pg/mL) and laser irradiated (0, 8 J/cm²) for 20 h; the culture medium was collected and used for ELISA. Secreted protein levels of (A) MMP-1 and (B) MMP-3 are represented as mean \pm SEM of three independent experiments (n = 3). *p < 0.05 compared to the IL-1 β group.

4. Discussion

Recently, LLLT was shown to reduce inflammatory reactions both in vitro and in vivo by regulating pro-inflammatory gene expression [40]. LLLT (904 nm) diminished inflammatory cell migration in a dose-dependent manner in a mouse model of lipopolysaccharide (LPS)-induced periodontitis, with 3 J/cm² being the most effective dose [41]. Furthermore, LLLT at 780 nm (7.7 J/cm²) suppressed IL-6 expression in a rat model of collagenase-induced tendinitis [42]; LLLT at 660 nm significantly reduced IL-6 and TNF- α expression in rat model of carrageenan-induced pleurisy [43]; and LLLT at 660 nm (8 J/cm²) reduced the expression of inflammatory markers such as IL-1 β , IL-6, and TNF- α in LPS-stimulated human adipose-derived stem cells [44]. However, the precise mechanism underlying the effect of high-frequency near-infrared diode laser (904 nm) on cartilage inflammation remains unknown. In this study, we investigated the effect of high-frequency near-infrared diode laser irradiation on cultured human chondrocytes (NHAC-Kn cells). To mimic the degenerative effect of osteoarthritic cartilage, NHAC-Kn cells were stimulated using human recombinant IL-1 β [45, 46]. IL-1 β is a pro-inflammatory cytokine that interferes with ECM turnover by accelerating cartilage matrix degradation and inducing chondrocyte apoptosis.

In this study, qPCR analysis revealed that IL-1 β significantly upregulated IL-1 β , IL-6, and TNF- α mRNA levels in NHAC-Kn cells and that these levels were significantly attenuated after irradiation of the IL-1 β -stimulated chondrocytes with high-frequency near-infrared diode laser at 4 or 8 J/cm². The gene expression of IL-1 β , IL-6, and TNF- α in rat models of acute joint inflammation [47, 48] and in the cartilage of rat models of OA [49] decreased significantly after LLLT (808 nm, 142 J/cm²) and laser irradiation (808 nm, 71 J/cm²) respectively. Moreover, photobiomodulation therapy (830 nm, 214 J/cm²) effectively reduced the OA-induced IL-1 β , IL-6, and TNF- α protein expression in experimental rat OA models [50]. Our results are consistent with the previous reports; however, the wavelengths, power numbers, frequency, and pulse numbers of laser irradiation differ.

MMPs are Zn⁺²- or Ca⁺²-dependent endopeptidases that degrade ECM components. The MMP family comprises 24 members, 23 of which are found in mammals [51, 52]. MMPs play a key role in pathological conditions such as inflammation, rheumatoid arthritis, OA, cardiovascular diseases, fibrosis, and cancer [52]. As an array of proteases, MMP-1, MMP-3, and MMP-13 degrade type II collagen and proteoglycans, causing cartilage proteolysis [53]. High concentrations of MMP-1 (collagenase-1), which is mainly produced by synoviocytes, was found in the synovial fluid of patients with joint lesions and OA. It degrades aggrecan and collagen types I, II, III, VII, X, and IX [54-58]. MMP-3 (stromelysin-1), which is produced by articular synovial cells, chondrocytes, fibroblasts, and macrophages, has the broadest substrate specificity among MMPs and degrades cartilage proteoglycans; collagen types III, IV, V, VII, and IX; laminin; and fibronectin. It has also been implicated in joint destruction in rheumatoid arthritis. MMP-9 (gelatinase B) is usually secreted by fibroblasts and inflammatory cells, which migrate to lesion sites, and can cleave native type IV and V collagens [59]. The presence of active MMP-9 in the synovial fluid has been reported. Because of limited substrate specificity, MMP-9 does not initiate direct joint destruction. As MMP-9 in synovial fluid is produced by inflammatory cells and platelets, MMP levels are influenced by inflammation and likely reflect joint inflammation [60]. MMP-13 (collagenase-3) is a member of the collagenase subfamily and is usually found in bone articular cartilage and chondrocytes [61]. MMP-13 was also found in synovial tissue and has been associated with OA and degradation of cartilage proteoglycans and collagen types I, II, and III [61, 63]. Moreover, MMP-13 has been suggested to be involved in pathways associated with MMP-9 activation [64, 65]. Therefore, MMP-13 may be considered as a critical component of the cellular machinery involved in regulating articular cartilage turnover and a potential therapeutic target for cartilage destruction [66]. Several studies have reported the effect of low-level laser irradiation on MMP synthesis and the associated pathological conditions [67-71].

In present study, high-frequency near-infrared diode laser irradiation at 4 and 8 J/cm² reduced MMP-1 and MMP-3 mRNA levels, compared with those in the IL-1 β stimulation groups. However, the MMP-9 and MMP-13 mRNA levels were not altered by laser irradiation at 4 or 8 J/cm². In addition, we assessed the protein expression and secreted levels of MMP-1 and MMP-3 by western

blotting and ELISA respectively. Laser irradiation at 8 J/cm² significantly reduced the IL-1β-stimulated increased in protein levels of MMP-1 and MMP-3.

LLLT (830 nm 1.5 J/cm²) was reported to significantly decrease the gene expression of MMP-3 at weeks 6 and 8 and that of MMP-1 and MMP-13 at week 8 in a rabbit model of anterior cruciate ligament transection (ACLT)-induced OA. [72]. Furthermore, LLLT significantly decreased the protein levels of MMP-9 in a rat model of papain-induced cartilage injury [73]. Thus, our results for MMP-1 and MMP-3 levels are consistent with those reported previously. However, the results for MMP-9 and MMP-13 levels are not consistent with these reports. This discrepancy may be attributed to the difference in the method for OA induction. In experimental animal models, OA is induced by ALCT or local papain administration. Our study is an in vitro study involving IL-1 β stimulation in human articular chondrocytes. In addition, the power, wavelengths, and pulses of the high-frequency diode laser are different from those of LLLT; therefore, the outcomes of these two laser therapies cannot be compared directly. Histological evaluation of the effects of high-frequency diode lasers using OA animal models is required.

Previous study demonstrated that LLLT suppresses inflammatory response of human adiposederived stem cells by increasing intracellular cyclic AMP level and subsequently decreasing NF-κB activity [44]. LLLT was also shown to suppress the activation of the NF-κB signaling pathway in LPStreated mesenchymal stem cells by inhibiting phosphorylation of p65 and $I\kappa B\alpha$, thereby exerting an anti-inflammatory effect [74]. It has been reported that IL-1β-induced increase in MMP-13 expression requires p38 activity, JNK activity, and NF-κB translocation but does not involve MEK, whereas the increase in MMP-1 expression requires p38 and MEK activity but does not involve JNK and NF-kB [75]. MMP-1 and MMP-3 expression in IL-1β-stimulated chondrosarcoma cells was suppressed by p38 and ERK inhibitors but not by JNK inhibitor, and MMP-13 expression was suppressed by p38 and JNK inhibitors but not ERK inhibitor [76]. These findings indicate that the signaling pathway for IL-1β-mediated regulation of MMP-13 is different from that for IL-1β-mediated regulation of MMP-1 and MMP-3 and may not involve MEK/ERK activities. Previous studies indicated that highfrequency diode laser irradiation affected ERK activity but not p38 and JNK activity [34, 35]. Our qPCR results show that high-frequency diode laser irradiation decreased the IL-1β-induced MMP-1 and MMP-3 expression but did not affect MMP-13 expression. Collectively, these findings suggest the involvement of the MEK/ERK signaling pathway in the IL-1β- and irradiation-mediated regulation of MMP-1 and MMP-3 expression in chondrocytes.

Because the biological effects of lasers are non-specific, indirect, transient, and complex, it is difficult to ascertain the precise effect of laser irradiation in cellular signaling pathways. One study reported that helium-neon laser activated the Akt signaling pathway [77], whereas another study conducted using the same laser reported that the laser inactivated this pathway [78]. Nevertheless, the detailed mechanism underlying the anti-inflammatory effect of laser irradiation remains poorly understood. Further studies are necessary to elucidate the precise mechanism underlying the effect of high-frequency diode laser irradiation in chondrocytes.

5. Conclusions

The present study demonstrates that high-frequency diode laser irradiation ameliorated inflammation and production of MMP-1 and MMP-3 in IL-1 β -stimulated human chondrocytes. Collectively, our findings highlight the potential applicability of high-frequency diode laser in reducing the inflammation and cartilage destruction observed in OA.

Funding: This research was funded by grants from the JSPS KAKENHI (grant numbers: 19K10385, 18K17256, and 18K17257).

Acknowledgments: This work was performed at the Research Center for Molecular Medicine, Hiroshima University.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Messier, S.P.; Callahan, L.F.; Beavers, D.P.; Queen, K.; Mihalko, S.L.; Miller, G.D.; Losina, E.; Katz, J.N.; Loeser, R.F.; Quandt, S.A.; et al. Weight-loss and exercise for communities with arthritis in North Carolina (we-can):design and rationale of a pragmatic, assessor-blinded, randomized controlled trial. *BMC Musculoskelet. Disord.* 2017, *8*, 91. DOI:10.1186/s12891-017-1441-4.
- 2. Jerosch, J. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: outlook on other nutrient partners especially omega-3 fatty acids. Int. J. Rheumatol. **2011**, 969012. DOI:10.1155/2011/969012.
- 3. Sanches, M.; Assis, L.; Criniti, C.; Fernandes, D.; Tim, C.; Renno, A.C.M. Chondroitin sulfate and glucosamine sulfate associated to photobiomoulation prevents degenerative morphological changes in an experimental model of osteoarthritis in rats. Lasers Med. Sci. **2018**, *33*, 549-557. DOI:10.1007/s10103-017-2401-9.
- 4. Goldring, M.B.; Otero, M. Inflammation in osteoarthritis. Curr. Opin. Rheumatol. **2011**, 23, 471-478. DOI:10.1097/BOR.0b013e328349c2b1.
- 5. Sellam, J. Berenbaum, F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat. Rev. Rheumatol. **2010**, *6*, 625-635. DOI:10.1038/nrrheum.2010.159.
- 6. van den Berg, W.B. The role of cytokines and growth factors in cartilage destruction in osteoarthritis and rheumatoid arthritis. Z. Rheumatol. **1999**, *58*, 136-141. DOI:10.1007/s003930050163.
- 7. Shlopov, B.V.; Lie, W.R.; Mainardi, C.L.; Cole, A.A.; Chubinskaya, S.; Hasty, K.A. Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum. **1997**, 40, 2065-2074. DOI:10.1002/art.1780401120.
- 8. Loeser, R.F. Molecular mechanisms of cartilage destruction in osteoarthritis. J. Musculoskelet. Nueronal. Interact. **2008**, *8*, 303-306.
- 9. Loeser, R.F. Molecular mechanisms of cartilage destruction: mechanics, inflammatory mediators, and aging collide. Arthritis Rheum. **2006**, *54*, 1357-1360. DOI:10.1002/art.21813.
- 10. Sarzi-Puttini, P.; Cimmino, M.A.; Scarpa, R.; Caporali, R.; Parazzini, F.; Zaninelli, A.; Atzeni, F.; Canesi, B. Osteoarthritis: an overview of the disease and its treatment strategies. Semin. Arthritis Rheum. **2005**, 35, 1-10. DOI:10.1016/j.semarthrit.2005.01.013.
- 11. Lohmander, L.S.; Roos, E.M. Clinical update: treating osteoarthritis. Lancet **2007**, *370*, 2082-2084. DOI:10.1016/S0140-6736(07)61879-0.
- 12. Ohno, S.; Schmid, T.; Tanne, Y.; Kamiya, T.; Honda, K.; Ohno-Nakahara, M.; Swentko, N.; Desai, T.A.; Tanne, K.; Knudson, C.B.; Knudson, W. Expression of superficial zone protein in mandibular condyle cartilage. Osteoarthr. Cartil. 2006, 14, 807-813. DOI:10.1016/j.joca.2006.02.002.
- 13. Kamiya, T.; Tanimoto, K.; Tanne, Y.; Lin Y.Y.; Kunimatsu, R.; Yoshioka, M.; Tanaka, N.; Tanaka, E.; Tanne, K. Effects of mechanical stimuli on the synthesis of superficial zone protein in chondrocytes. J. Biomed. Mater. Res. A. **2010**, *92*, 801-805. DOI:10.1002/jbm.a.32295.
- 14. Asakawa-Tanne, Y.; Su, S.; Kunimatsu, R.; Hirose, N.; Mitsuyoshi, T.; Okamoto, Y.; Tanaka, E.; Tanne, K.; Tanimoto, K. Effects of enzymatic degradation after loading in temporomandibular joint. J. Dent. Res. 2015, 94, 337-343. DOI:10.1177/0022034514560588.
- 15. Tanne, K. Degenerative changes of articular cartilage in association with mechanical stimuli. Jap. Dent. Sci. Rev. **2008**, *44*, 38-47. DOI:10.1016/j.jdsr.2007.10.004.
- 16. McAlindon, T.E.; Bannuru, R.R.; Sullivan, M.C.; Arden, N.K.; Berenbaum, F.; Bierma-Zeinstra, S.M.; Hawker, G.A.; Henrotin, Y.; Hunter, D.J.; Kawaguchi, H.; et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr. Cartil. 2014, 22, 363-388. DOI:10.1016/j.joca.2014.01.003.
- 17. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis. Rheum. 2000, 43, 1905-1915. DOI:10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P.
- 18. Brown, G.A. AAOS clinical practice guideline: treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J. Am. Acad. Orthop. Surg. **2013**, *21*, 577-579. DOI:10.5435/JAAOS-21-09-577.
- 19. Su, S.C.; Tanimoto, K.; Tanne, Y.; Kunimatsu, R.; Hirose, N.; Mitsuyoshi, T.; Okamoto, Y.; Tanne, K.; Celecoxib exerts protective effects on extracellular matrix metabolism of mandibular condylar chondrocytes under excessive mechanical stress. Osteoarthr. Cartil. **2014**, 22, 845-851. DOI:10.1016/j.joca.2014.03.011.

- Yanoshita, M.; Hirose, N.; Okamoto, Y.; Sumi, C.; Takano, M.; Nishiyama, S.; Asakawa-Tanne, Y.; Horie, K.; Onishi, A.; Yamauchi, Y.; et al. Cyclic tensile strain upregulates pro-inflammatory cytokine expression via FAK-MAPK signaling in chondrocytes. Inflammation. 2018, 41, 1621-1630. DOI:10.1007/s10753-018-0805-8.
- 21. Sumi, C.; Hirose, N.; Yanoshita, M.; Takano, M.; Nishiyama, S.; Okamoto, Y.; Asakawa, Y.; Tanimoto, K. Semaphorin 3A inhibits inflammation in chondrocytes under excessive mechanical stress. Mediators Inflamm. 2018, 8, 5703651. DOI:10.1155/2018/5703651.
- 22. Rodriguez, L.A.G.; Hernandez-Diaz, S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. **2001**, *3*, 98-101. DOI:10.1186/ar146.
- 23. Meek, I.L.; Van de Laar M.A.; Vonkeman, H.E. Non-steroidal anti-inflammatory drugs: an overview of cardiovascular risks. Pharmaceuticals (Basel) **2010**, *3*, 2146-2162. DOI:10.3390/ph3072146.
- 24. Zeng, C.; Li, H.; Yang, T.; Deng, Z.H.; Yang, Y.; Zhang, Y.; Ding, X.; Lei, G.H. Effectiveness of continuous and pulsed ultrasound for the management of knee osteoarthritis: a systematic review and network meta-analysis. Osteoarthr. Cartil. **2014**, *22*, 1090-1099. DOI:10.1016/j.joca.2014.06.028.
- 25. Melo, M.D.O.; Pompeo, K.D.; Brodt, G.A.; Baroni, B.M.; da Silva Junior, D.P.; Vaz, M.A. Effects of neuromuscular electrical stimulation and low-level laser therapy on the muscle architecture and functional capacity in elderly patients with knee osteoarthritis: a randomized controlled trial. Clin. Rehabil. **2015**, *29*, 570-580. DOI:10.1177/0269215514552082.
- 26. Uthman, O.A.; van der Windt, D.A.; Jordan, J.L.; Dziedzic, K.S.; Healey, E.L.; Peat, G.M.; Foster, N.E. Exercise for lower limb osteoarthritis: systematic review incorporating trial sequential analysis and network meta-analysis. Br. J. Sports Med. 2014, 48, 1579. DOI:10.1136/bmj.f5555.
- 27. Tenti, S.; Cheleschi, S.; Galeazzi, M.; Fioravanti, A. Spa therapy: can be a valid option for treating knee osteoarthritis? Int. J. Biometeorol. **2015**, *59*, 1133-1143. DOI:10.1007/s00484-014-0913-6.
- 28. Zhang, W.; Moskowitz, R.W.; Nuki, G.; Abramson, S.; Altman, R.D.; Arden, N.; Bierma-Zeinstra, S.; Brandt, K.D.; Croft, P.; Doherty, M.; et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr. Cartil. 2008, 16, 137-162. DOI:10.1016/j.joca.2007.12.013.
- 29. Bjordal, J.M.; Johnson, M.I.; Lopes-Martins, R.A.; Bogen, B.; Chow, R.; Ljunggren, A.E. Short-term efficacy of physical interventions in osteoarthritic knee pain. A systematic review and meta-analysis of randomised placebo-controlled trials. BMC Musculoskelet. Disord. 2007, 8, 51.
- 30. Baltzer, A.W.; Ostapczuk, M.S.; Stosch, D. Positive effects of low level laser therapy (LLLT) on Bouchard's and Heberden's osteoarthritis. Lasers Surg. Med. **2016**, *48*, 498-504.
- 31. Langella, L.G.; Casalechi, H.L.; Tomazoni S.S.; Johnson, D.S.; Albertini, R.; Pallotta, R.C.; Marcos R.L.; de Carvalho P.T.C.; Leal-Junior E.C.P. Photobiomodulation therapy (PBMT) on acute pain and inflammation in patients who underwent total hip arthroplasty-a randomized, triple-blind, placebo-controlled clinical trial. Lasers Med. Sci. **2018**, *33*, 1933-1940.
- 32. Hashmi, J.T.; Huang, Y.Y.; Sharma, S.K.; Kurup, D.B.; De Taboada, L.; Carroll, J.D.; Hamblin, M.R. Effect of pulsing in low-level light therapy. Lasers Surg. Med. **2010**, 42, 450-466.
- 33. Joensen, J.; Ovsthus, K.; Reed, R.K.; Hummelsund, S.; Iversen, V.V.; Lopes-Martins, R.A.; Bjordal, J.M. Skin penetration time- profiles for continuous 810 nm and superpulsed 904 nm lasers in a rat model. Photomed. Laser. Surg. 2012, 30, 688-694.
- 34. Ejiri, K.; Aoki, A.; Yamaguchi, Y.; Ohshima, M.; Izumi, Y. High-frequency low-level diode laser irradiation promotes proliferation and migration of primary cultured human gingival epithelial cells. Lasers Med. Sci. **2014**, *29*, 1339-1347.
- 35. Kunimatsu, R.; Gunji, H.; Tsuka, Y.; Yoshimi, Y.; Awada, T.; Sumi, K.; Nakajima, K.; Kimura, A.; Hiraki, T.; Abe, T.; et al. Effects of high-frequency near-infrared diode laser irradiation on the proliferation and migration of mouse calvarial osteoblasts. Lasers Med. Sci. **2018**, *33*, 959-966.
- 36. Noda, M.; Aoki, A.; Mizutani, K.; Lin, T.; Komaki, M.; Shibata, S.; Izumi, Y. High-frequency pulsed low-level diode laser therapy accelerates wound healing of tooth extraction socket: An in vivo study. Lasers Surg. Med. **2016**, *48*, 955-964.
- 37. Marini, I.; Gatto, M.R.; Bonetti, G.A. Effects of superpulsed low-level laser therapy on temporomandibular joint pain. Clin. J. Pain **2010**, *26*, 611-616.

- 38. Kheshie, A.R.; Alayat, M.S.; Ali, M.M. High-intensity versus low-level laser therapy in the treatment of patients with knee osteoarthritis: a randomized controlled trial. Lasers Med. Sci. **2014**, *29*, 1371-1376.
- 39. Gunji, H.; Kunimatsu, R.; Tsuka, Y.; Yoshimi, Y.; Sumi, K.; Awada, T.; Nakajima, K.; Kimura, A.; Hiraki, T.; Hirose, N.; et al. Effect of high-frequency near-infrared diode laser irradiation on periodontal tissues during experimental tooth movement in rats. Lasers Surg. Med. **2018**, *50*, 772-780.
- 40. Bortone, F.; Santos, H.A.; Albertini, R.; Pesquero, J.B.; Costa, M.S.; Silva, J.A.Jr. Low level laser therapy modulates kinin receptors mRNA expression in the subplantar muscle of rat paw subjected to carrageenan-induced inflammation. Int. Immunopharmacol. **2008**, *8*, 206-210.
- 41. Correa, F.; Martins, R.A.B.L., Correa, J.C.; Iversen, V.V.; Joenson, J.; Bjordal, J.M. Low-level laser therapy (GaAs lambda = 904 nm) reduces inflammatory cell migration in mice with lipopolysaccharide-induced peritonitis. Photomed. Laser Surg. 2007, 25, 245-249.
- 42. Pires, D.; Xavier, M.; Araujo, T.; Silva, J.A.Jr.; Aimbire, F.; Albertini, R. Low-level laser therapy (LLLT; 780 nm) acts differently on mRNA expression of anti- and pro-inflammatory mediators in an experimental model of collagenase-induced tendinitis in rat. Lasers Med. Sci. **2011**, *26*, 85-94.
- 43. Boschi, E.S.; Leite, C.E.; Saciura, V.C.; Caberlon, E.; Lunardelli, A.; Bitencourt, S.; Melo, D.A.; Oliveira, J.R. Anti-inflammatory effects of low-level laser therapy (660 nm) in the early phase in carrageenan-induced pleurisy in rat. Lasers Surg. Med. 2008, 40, 500-508.
- 44. Wu, J.Y.; Chen, C.H.; Wang, C.Z.; Ho, M.L.; Yeh, M.L.; Wang, Y.H. Low-power laser irradiation suppresses inflammatory response of human adipose-derived stem cells by modulating intracellular cyclic AMP level and NF-kappaB activity. PLoS One **2013**, *8*, e54067.
- 45. Citalingam, K.; Zareen, S.; Shaari, K.; Ahmad, S. Effects of *Payena dasyphylla* (Miq.) on hyaluronidase enzyme activity and metalloproteinases protein expressions in interleukin-1β stimulated human chondrocytes cells. BMC Complement. Altern. Med. **2013**, *13*, 213.
- 46. Lei, J.; Fu, Y.; Zhuang, Y.; Zhang, K.; Lu, D. LncRNA SNHG1 alleviates IL-1β-induced osteoarthritis by inhibiting miR-16-5p-mediated p38 MAPK and NF-κB signaling pathways. Biosci Rep 2019, 39, BSR20191523.
- 47. Alves, A.C.; Vieira, R.; Leal-Junior, E.; dos Santos, S.; Ligeiro, A.P.; Albertini, R.; Junior, J.; de Carvalho, P. Effect of low-level laser therapy on the expression of inflammatory mediators and on neutrophils and macrophages in acute joint inflammation. Arthritis Res. Ther. **2013**, *15*, R116.
- 48. dos Santos S.A.; Alves, A.C.; Leal-Junior, E.C.; Albertini, R.; Vieira, R.P.; Ligeiro, A.P.; Junior, J.A.; de Carvalho, P.D.T. Comparative analysis of two low-level laser doses on the expression of inflammatory mediators and on neutrophils and macrophages in acute joint inflammation. Lasers Med. Sci. **2014**, *29*, 1051-1058.
- 49. Stancker, T.G.; Vieira, S.S.; Serra, A.J.; do Nascimento Lima, R.; dos Santos Feliciano, R.; Silva, J.A.Jr.; dos Santos, S.A.; dos Santos Vieira, M.A.; Simões, M.C.B.; Leal-Junior, E.C.; et al. Can photobiomodulation associated with implantation of mesenchymal adipose-derived stem cells attenuate the expression of MMPs and decrease degradation of type II collagen in an experimental model of osteoarthritis? Lasers Med. Sci. 2018, 33, 1073-1084.
- 50. Tomazoni, S.S.; Leal-Junior, E.C.; Pallotta, R.C.; Teixeira, S.; de Almeida, P.; Lopes-Martins, R.Á. Effects of photobiomodulation therapy, pharmacological therapy, and physical exercise as single and/or combined treatment on the inflammatory response induced by experimental osteoarthritis. Lasers Med. Sci. 2017, 32, 101-108.
- 51. Alameddine, H.S.; Morgan, J.E. Matrix metalloproteinase and tissue inhibitor of metalloproteinases in inflammation and fibrosis of skeletal muscles. J. Neromuscul. Dis. **2016**, *3*, 455–473.
- 52. Yamamoto, T.; Murphy, G.; Troeberg, L. Extracellular regulation of metalloproteinases. Matrix Biol. **2015**, 44, 255–263.
- 53. Naito, K.; Takahashi, M.; Kushida, K.; Suzuki, M.; Ohishi, T.; Miura, M.; Inoue, T.; Nagano, A. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases- 1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis. Rheumatology (Oxford) 1999, 38, 510-515.
- 54. Farley, J.; Dejica, V.C.; Mort, J.S. Proteases and cartilage degra- dation in osteoarthritis. Principles of osteoarthritis-its definition, character, derivation and modality-related recognition. Dr. Bruce M. Rothschild (Ed.), InTech, 2012.
- 55. Goldring, M.B. Articular cartilage degradation in osteoarthritis. HSS J. 2012, 8, 7-9.

- 56. Dejica, V.M.; Mort, J.S.; Laverty, S.; Antoniou, J.; Zukor, D.J.; Tanzer, M.; Poole, A.R. Increased type II collagen cleavage by cathepsin K and collagenase activities with aging and osteoarthritis in human articular cartilage. Arthritis Res. Ther. **2012**, *14*, R113.
- 57. Kuroda, K.; Kabata, T.; Hayashi, K.; Maeda, T.; Kajino, Y.; Iwai, S.; Fujita, K.; Hasegawa, K.; Inoue, D.; Sugimoto, N.; et al. The paracrine effect of adipose-derived stem cells inhibits osteoarthritis progression. BMC Musculoskelet. Disord. **2015**, *16*, 236.
- 58. ter Huurne, M.; Schelbergen, R.; Blattes, R.; Blom, A.; de Munter, W.; Grevers, L.C.; Jeanson, J.; Noël, D.; Casteilla, L.; Jorgensen, C.; et al. Anti-inflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis. Arthritis Rheum. **2012**, *64*, 3604-3613.
- 59. Guerra, F.D.R.; Vieira, G.P.; Marques, P.P.; Oliveira, L.P.; Pimentel, E.R. Low level laser therapy accelerates the extracellular matrix reorganization of in-flamed tendon. Tissue Cell **2017**, *49*, 483-488.
- 60. Mitchell, P.G.; Magna, H.A.; Reeves, L.M.; Lopresti-Morrow, L.L.; Yocum, S.A.; Rosner, P.J.; Geoghegan K.F.; Hambor, J.E. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J. Clin. Invest. 1996, 97, 761-768.
- 61. Singh, A.; Rayasekaran, N.; Hartenstein, B. Collagenase-3 (MMP-13) deficiency protects C57BL/6 mice from antibody- induced arthritis. Arthritis Res. Ther. **2013**, *15*, 1-7.
- 62. Li, H.; Wong, D.; Yuan, Y.; Min, J. New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis. Arthritis Res. Ther. **2017**, *19*, 1-12.
- 63. Fosang, A.J.; Last, K.; Knauper, V.; Murphy, G.; Neame, P.J. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FESB Lett. 1996, 12, 17-20.
- 64. Alameddine, H.S.; Morgan, J.E. Matrix metalloproteinase and tissue inhibitor of metalloproteinases in inflammation and fibrosis of skeletal muscles. J. Neromuscul. Dis. **2016**, *3*, 455-473.
- 65. Klein, T.; Bischoff, R. Physiology and pathophysiology of matrix metalloproteinases. Amino Acids **2011**, 41, 271-290.
- 66. Singh, A.; Rayasekaran, N.; Hartenstein, B. Collagenase-3 (MMP-13) deficiency protects C57BL/6 mice from antibody-induced arthritis. Arthritis Res. Ther. **2013**, *15*: 1-7.
- 67. Bonnas, C.; Chou, J.; Werb, Z. Remodeling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. **2014**, *15*, 786-801.
- 68. Guerra, F.D.R.; Vieira, G.P.; Marques, P.P.; Oliveira, L.P.; Pimentel, E.R. Low level laser therapy accelerates the extracellular matrix reorganization of in-flamed tendon. Tissue Cell **2017**, *49*, 483-488.
- 69. Guerra F.D.R.; Vieira, C.P.; Almeida, M.S.; Oliveira, L.P.; Aro, A.A.; Pimentel, E.R. LLLT improves tendon healing through increase of MMP activity and collagen synthesis. Laser Med. Sci. **2013**, *28*, 1281-1288.
- 70. Lemos, G.A.; Rissi, R.; Pires, I.L.S.; de Oliveira, L.P.; de Aro, A.A.; Pimentel, E.R.; Palomari, E.T. Low-level laser therapy stimulates repair and reduces the extracellular matrix degradation in rats with induced arthritis in the temporomandibular joint. Lasers Med. Sci. **2016**, *31*, 1051-1059.
- 71. Casalechi, H.L.; Leal-Junior, E.C.P.; Xavier, M.; Silva, J.A.; de Carvalho, P.D.T.C.; Aimbire, F.; Albertini, R. Low-level laser therapy in experimental model of collagenase-induced tendi- nitis in rats: effects in acute and chronic inflammatory phases. Laser Med. Sci. **2012**, *28*, 989-995.
- 72. Wang, P.; Liu, C.; Yang, X.; Zhou, Y.; Wei, X.; Ji, Q.; Yang, L.; He, C. Effects of low-level laser therapy on joint pain, synovitis, anabolic, and catabolic factors in a progressive osteoarthritis rabbit model. Lasers Med. Sci. **2014**, *29*, 1875-1885.
- 73. Alves, A.C.; Albertini, R.; dos Santos, S.A.; Leal-Junior, E.C.; Santana, E.; Serra, A.J.; Silva, J.A.Jr.; de Carvalho P.T.D.C. Effect of low-level laser therapy on metalloproteinase MMP-2 and MMP-9 production and percentage of collagen types I and III in a papain cartilage injury model. Lasers Med. Sci. **2014**, 29, 911-919.
- 74. Yin, K.; Zhu, R.; Wang, S.; Zhao, R.C. Low level laser (LLL) attenuate LPS-induced inflammatory responses in mesenchymal stem cells via the suppression of NF-κB signaling pathway in vitro. PLoS One **2017**, *12*, e0179175.
- 75. Mengshol, J.A.; Vincenti, M.P.; Coon, C.I.; Barchowsky, A.; Brinckerhoff, C.E. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000, 43, 801-811.
- 76. Zeng, L.; Rong, X.F.; Li, R.H.; Wu, X.Y. Icariin inhibits MMP1, MMP3 and MMP13 expression through MAPK pathways in IL1beta-stimulated SW1353 chondrosarcoma cells. Mol. Med. Rep. **2017**, *5*, 2853-2858.

- 77. Zhang, L.; Xing, D.; Gao, X.; Wu, S. Low-power laser irradiation promotes cell proliferation by activating PI3K/Akt pathway. J. Cell Physiol. **2009**, *219*, 553-562.
- 78. Huang, L.; Wu, S.; Xing, D. High fluence low-power laser irradiation induces apoptosis via inactivation of Akt/GSK3beta signaling pathway. J. Cell Physiol. **2011**, 226, 588-601.